Recro Pharma, Inc. (REPH) Stock Analysis

Recro Pharma, Inc. (REPH) Healthcare & Pipeline Overview

Recro Pharma, Inc. is a contract development and manufacturing organization focused on small molecule therapeutics, offering a diverse range of dosage forms and services to clients in the pharmaceutical industry, thereby enhancing its competitive edge in the healthcare sector.

What Is the Investment Thesis for REPH?

The company has a market capitalization of $177M and operates with a profit margin of -14.0%, indicating potential for improvement as it scales operations. With a gross margin of 19.5%, Recro Pharma is positioned to leverage its diverse product offerings and expand its client base in the growing pharmaceutical sector. Key growth catalysts include increasing demand for specialized manufacturing services and the expansion of its product lines into new therapeutic areas. However, the company faces risks such as regulatory challenges and competitive pressures from larger firms in the industry. Investors should monitor Recro Pharma's operational efficiency and market penetration strategies as indicators of future performance.

Based on FMP financials and quantitative analysis

REPH Key Highlights

Market Cap of $177M indicates a small but significant presence in the drug manufacturing sector.

• Profit Margin of -14.0% highlights current challenges but potential for operational improvements.
• Gross Margin of 19.5% reflects the company's ability to manage costs amid competitive pressures.
• Beta of 1.12 suggests volatility in stock performance relative to the market.
• No dividend yield indicates a focus on reinvestment for growth rather than returning capital to shareholders.

Who Are REPH's Competitors?

REPH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are REPH's Key Strengths?

Strong expertise in small molecule therapeutic development.

• Diverse range of dosage forms and manufacturing capabilities.
• Established reputation for quality and reliability.

What Are REPH's Weaknesses?

Negative profit margin indicating current operational challenges.

• Limited brand recognition compared to larger competitors.
• Dependence on a small number of key clients for revenue.

What Could Drive REPH Stock Higher?

Expansion of service offerings to include new therapeutic areas by Q4 2026.

• Development of partnerships with pharmaceutical companies for contract manufacturing.
• Implementation of operational improvements to enhance efficiency and reduce costs.

What Are the Key Risks for REPH?

Financial-distress signal — its Altman Z-Score of -1.06 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-22.4%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Regulatory changes that could impact manufacturing processes.
• Competitive pressures from larger firms in the drug manufacturing sector.
• Fluctuations in demand for contract manufacturing services due to market conditions.

What Are the Growth Opportunities for REPH?

• Growth opportunity 1: The global contract manufacturing market is expected to reach $175 billion by 2026, driven by increasing outsourcing trends among pharmaceutical companies. Recro Pharma can capitalize on this growth by expanding its service offerings and enhancing its operational capabilities to meet the rising demand for specialized manufacturing services.
• Growth opportunity 2: The rise in personalized medicine is creating a demand for tailored therapeutic solutions. Recro Pharma's expertise in small molecule therapeutics positions it to develop and manufacture customized drug formulations, tapping into a market projected to grow at a CAGR of 10% over the next five years.
• Growth opportunity 3: The increasing prevalence of chronic diseases is driving the need for innovative drug delivery systems. Recro Pharma's capabilities in sterile injectables and advanced dosage forms can enable it to attract partnerships with pharmaceutical companies focused on developing next-generation therapies.
• Growth opportunity 4: Expansion into international markets presents a significant opportunity for Recro Pharma. As global healthcare spending continues to rise, the company can leverage its manufacturing expertise to establish partnerships with foreign pharmaceutical firms, enhancing its revenue streams.
• Growth opportunity 5: The trend towards sustainability in pharmaceuticals is prompting companies to seek eco-friendly manufacturing solutions. Recro Pharma can differentiate itself by adopting green manufacturing practices, appealing to environmentally conscious clients and potentially opening new market segments.

What Threats Does REPH Face?

• Intense competition from larger, established firms in the industry.
• Regulatory challenges that could impact operational efficiency.
• Market volatility and economic downturns affecting client budgets.

What Are REPH's Competitive Advantages?

• Expertise in small molecule therapeutics provides a competitive edge.
• Established reputation for quality and reliability in manufacturing.
• Diverse service offerings cater to a wide range of client needs.
• Strong relationships with clients foster loyalty and repeat business.
• Ability to adapt to changing market demands enhances resilience.

What Does REPH Do?

Founded in 2007 and based in Exton, Pennsylvania, Recro Pharma, Inc. initially operated as Recro Pharma I, Inc. before rebranding in August 2008. The company specializes in contract development and manufacturing services for various therapeutic dosage forms, primarily focusing on small molecule therapeutics. Recro Pharma offers a comprehensive suite of products, including oral solid doses, sterile injectables, oral liquids, tablets, topicals, liquid/powder filled capsules, ophthalmic droppers, liposomes, and nano/microparticles. Its capabilities extend to aseptic fill/finish, lyophilization, packaging, and logistics services, making it a versatile partner for pharmaceutical companies. With a workforce of 185 employees, Recro Pharma has positioned itself as a reliable provider in the competitive landscape of drug manufacturing. The company's strategic focus on quality and innovation has allowed it to cater to both domestic and international markets, enhancing its reputation and client base. As the healthcare industry evolves, Recro Pharma continues to adapt its offerings to meet the changing needs of its clients, ensuring it remains a relevant player in the industry.

What Products and Services Does REPH Offer?

• Develops and manufactures a wide range of therapeutic dosage forms.
• Specializes in small molecule therapeutic development.
• Offers services including aseptic fill/finish and lyophilization.
• Provides packaging and logistics services for pharmaceutical products.
• Focuses on both domestic and international markets.
• Engages in the production of oral solid doses, sterile injectables, and topicals.

How Does REPH Make Money?

• Generates revenue through contract manufacturing agreements with pharmaceutical companies.
• Offers a diverse array of dosage forms and services to meet client needs.
• Focuses on specialized manufacturing processes to differentiate from competitors.
• Engages in long-term partnerships with clients for ongoing projects.
• Utilizes a flexible operational model to adapt to changing market demands.

What Industry Does REPH Operate In?

The drug manufacturing industry, particularly in the specialty and generic segments, is experiencing robust growth, driven by increasing healthcare demands and advancements in pharmaceutical technologies. The global contract development and manufacturing market is projected to grow significantly, fueled by the rising need for specialized services among pharmaceutical companies. Recro Pharma, Inc. operates in a competitive landscape, facing challenges from larger firms with more extensive resources. However, its focus on small molecule therapeutics and diverse service offerings positions it well to capture market share in niche segments.

Who Are REPH's Key Customers?

• Pharmaceutical companies seeking contract manufacturing services.
• Biotechnology firms developing new therapies.
• Healthcare organizations requiring specialized drug formulations.
• Research institutions needing support for clinical trials.
• International clients looking for reliable manufacturing partners.

How Recro Pharma, Inc. Is Valued

Recro Pharma, Inc. carries a market capitalization of $177M, placing it in the micro-cap category.

Company Profile

Recro Pharma, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Malvern, US. The company is led by CEO Geraldine Henwood. REPH has traded publicly since 2014.

Return on equity for Recro Pharma, Inc. stands at -22.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -8.6%, showing how much profit it generates from its asset base. Its free cash flow yield is -10.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.07 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -12.7%, the inverse of the P/E and a quick read on earnings relative to price.

Recro Pharma, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -1.06 places it in the distress zone, a signal of elevated financial risk.

The most recent 12 insider filings for Recro Pharma, Inc. break down as 6 sales and 6 purchases. On net that is roughly 328K shares acquired (about $132K) — insiders putting money in tends to read as conviction.

REPH Financials

REPH Latest News

What Investors Ask About Recro Pharma, Inc. (REPH) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources